EMERGENT BIOSOLUTIONS INC (EBS) Stock Price, Quote, News and Overview
NYSE:EBS - New York Stock Exchange, Inc. - US29089Q1058 - Common Stock - Currency: USD
EBS Quote, Performance and Key Statistics
6.94
+0.21 (+3.12%)
The current stock price of EBS is 6.94 USD. In the past month the price increased by 47.03%. In the past year, price increased by 45.8%.
EBS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 327.00B | ||
| AMGN | AMGEN INC | 13.25 | 147.86B | ||
| GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
| ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
| NTRA | NATERA INC | N/A | 21.01B | ||
| BIIB | BIOGEN INC | 8.25 | 19.13B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B |
Related stock screener links
About EBS
Company Profile
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 900 full-time employees. The company went IPO on 2006-11-15. The company is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Company Info
EMERGENT BIOSOLUTIONS INC
300 Professional Dr
Gaithersburg MARYLAND 20879 US
CEO: Robert G. Kramer
Employees: 900
Phone: 12406313200
EMERGENT BIOSOLUTIONS INC / EBS FAQ
What is the stock price of EMERGENT BIOSOLUTIONS INC today?
The current stock price of EBS is 6.94 USD. The price increased by 3.12% in the last trading session.
What is the ticker symbol for EMERGENT BIOSOLUTIONS INC stock?
The exchange symbol of EMERGENT BIOSOLUTIONS INC is EBS and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is EBS stock listed?
EBS stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for EMERGENT BIOSOLUTIONS INC stock?
7 analysts have analysed EBS and the average price target is 13.77 USD. This implies a price increase of 98.41% is expected in the next year compared to the current price of 6.94. Check the EMERGENT BIOSOLUTIONS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EMERGENT BIOSOLUTIONS INC worth?
EMERGENT BIOSOLUTIONS INC (EBS) has a market capitalization of 377.12M USD. This makes EBS a Small Cap stock.
How many employees does EMERGENT BIOSOLUTIONS INC have?
EMERGENT BIOSOLUTIONS INC (EBS) currently has 900 employees.
What are the support and resistance levels for EMERGENT BIOSOLUTIONS INC (EBS) stock?
EMERGENT BIOSOLUTIONS INC (EBS) has a support level at 5.87 and a resistance level at 10.15. Check the full technical report for a detailed analysis of EBS support and resistance levels.
Is EMERGENT BIOSOLUTIONS INC (EBS) expected to grow?
The Revenue of EMERGENT BIOSOLUTIONS INC (EBS) is expected to decline by -25.78% in the next year. Check the estimates tab for more information on the EBS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EMERGENT BIOSOLUTIONS INC (EBS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EBS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EBS, evaluating the profitability, health, valuation and growth aspects
- EMERGENT BIOSOLUTIONS INC (EBS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EMERGENT BIOSOLUTIONS INC (EBS) Sales and EPS estimates to see what analysts future expectations are.
- EMERGENT BIOSOLUTIONS INC (EBS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EMERGENT BIOSOLUTIONS INC (EBS) Insider and Institutional Ownership to learn about the owners and their transactions.
- EMERGENT BIOSOLUTIONS INC (EBS) Stock Chart to make your own analysis
- EMERGENT BIOSOLUTIONS INC (EBS) Latest news and press-releases to stay up to date.
Does EMERGENT BIOSOLUTIONS INC (EBS) stock pay dividends?
EBS does not pay a dividend.
When does EMERGENT BIOSOLUTIONS INC (EBS) report earnings?
EMERGENT BIOSOLUTIONS INC (EBS) will report earnings on 2025-08-04.
What is the Price/Earnings (PE) ratio of EMERGENT BIOSOLUTIONS INC (EBS)?
EMERGENT BIOSOLUTIONS INC (EBS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.19).
What is the Short Interest ratio of EMERGENT BIOSOLUTIONS INC (EBS) stock?
The outstanding short interest for EMERGENT BIOSOLUTIONS INC (EBS) is 14.62% of its float. Check the ownership tab for more information on the EBS short interest.
EBS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to EBS. When comparing the yearly performance of all stocks, EBS is one of the better performing stocks in the market, outperforming 87.48% of all stocks.
EBS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EBS. EBS has a bad profitability rating. Also its financial health evaluation is rather negative.
EBS Financial Highlights
Over the last trailing twelve months EBS reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS increased by 88.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.72% | ||
| ROE | -39.48% | ||
| Debt/Equity | 1.37 |
EBS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 74% to EBS. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 332.95% and a revenue growth -25.78% for EBS